20

25

What is claimed is:

1. A method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a 5-HT_{1F} receptor agonist which activates the human 5-HT_{1F} receptor at least ten-fold more than it activates each of the human 5-HT_{1A}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2C}, 5-HT₃, 5-HT₄, and 5-HT₇ receptors.

- 2. The method of claim 1, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least ten-fold more than it activates each of the 5-HT_{1B} , 5-HT_{1E} , 5-HT_{2B} , 5-HT_{5A} , 5-HT_{5B} , and 5-HT_{6} receptors.
- 3. The method of claim 1, wherein the 5-HT $_{1F}$ receptor agonist also activates the human 5-HT $_{1F}$ receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.
- 4. The method of claim 1, wherein the 5-HT $_{1F}$ receptor agonist also activates the human 5-HT $_{1F}$ receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.
- 5. The method of claim 1, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human dopamine D_1 , D_2 , D_3 , and D_5 receptors.
- 35 6. The method of claim 1, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it


- 30 -

activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

- 7. The method of claim 1, wherein the 5-HT_{1F} receptor agonist activates the human 5-HT_{1F} receptor at least 50-fold more than it activates each of the human 5-HT_{1A} , 5-HT_{1D} , 5-HT_{2A} , 5-HT_{2C} , 5-HT_3 , 5-HT_4 , and 5-HT_7 receptors.
- 10 8. The method of claim 7, wherein the $5-\mathrm{HT_{1F}}$ receptor agonist additionally activates the human $5-\mathrm{HT_{1F}}$ receptor at least $50-\mathrm{fold}$ more than it activates each of the human $5-\mathrm{HT_{1B}}$, $5-\mathrm{HT_{2B}}$, $5-\mathrm{HT_{5A}}$, $5-\mathrm{HT_{5B}}$, and $5-\mathrm{HT_{6}}$ receptors.
- 9. The method of claim 7, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.
- 10. The method of claim 7, wherein the 5-HT_{1F} receptor agonist also activates the human 5-HT_{1F} receptor at least ten-fold more than it activates the human histamine H_1 and H_2 receptors.
- 11. The method of claim 7, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ 30 receptor at least ten-fold more than it activates the human dopamine D_1 , D_2 , D_3 , and D_5 receptors.
- 12. The method of claim 7, wherein the 5-HT $_{1F}$ receptor agonist also activates the human 5-HT $_{1F}$ receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

30

35




- 14. The method of claim 13, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 100-fold more than it activates each of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, and 5-HT₆ receptors.
- 15. The method of claim 13, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.
- 20 The method of claim 13, wherein the $5-HT_{1F}$ 16. receptor agonist also activates the human $5-HT_{1E}$ receptor at least ten-fold more than activates the human histamine H_1 and H_2 receptors.
 - 17. The method of claim 13, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human dopamine D_1 , D_2 , D_3 , and D_5 receptors.
 - 18. The method of claim 13, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.

15

30

35



- 20. The method of claim 19, wherein the 5-HT_{1F} receptor agonist additionally activates the human 5-HT_{1F} receptor at least 200-fold more than it activates each of the human 5-HT_{1B}, 5-HT_{1E}, 5-HT_{2B}, 5-HT_{5A}, 5-HT_{5B}, and 5-HT₆ receptors.
 - 21. The method of claim 19, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates any human α_2 adrenoceptor or any human β adrenoceptor.
- The method of claim 19, wherein the $5-\mathrm{HT}_{\mathrm{1F}}$ 22. 20 receptor agonist also activates the human ${\rm 5\text{-}HT_{1F}}$ receptor least ten-fold at than more activates the human histamine Η, and H_2 receptors.
- 25 23. The method of claim 19, wherein the $5-HT_{1F}$ receptor agonist also activates the human $5-HT_{1F}$ receptor at least ten-fold more than it activates the human dopamine D_1 , D_2 , D_3 , and D_5 receptors.
 - 24. The method of claim 19, wherein the 5-HT $_{1F}$ receptor agonist also activates the human 5-HT $_{1F}$ receptor at least ten-fold more than it activates the human α_{1A} adrenoceptor and the human α_{1B} adrenoceptor.